. In other experiments, injected oocytes were separated into pools, and all oocytes of each pool were subjected to the same concen-
. CGRP, one of the most potent vasodilators known (3) , may also be a neuromodulator (4, 5) . CGRP has a plethora of functions in the body. Aside from its vasodilatory and neuromodulatory actions, CGRP has been proposed to increase acetylcholine receptor synthesis at the neuromuscular junction (6) and to desensitize the acetylcholine receptor at the neuromuscular junction and the efferent synapses of the inner ear (5, 7) . CGRP-containing efferent fibers from the brainstem synapse at the inner ear end-organ sites, perhaps contributing to the processes responsible for the detection of auditory signals in the presence of background noise (8, 9) . Additionally, CGRP has been implicated as a growth factor for human endothelial cells (10) and shown to inhibit antigen.presentation by Langerhans cells in epidermal cell culture (11) .
Protein purification strategies based on cross-linking cell extracts to CGRP followed by SDS/PAGE analysis have identified candidate proteins for the CGRP receptor and its complex, with molecular masses of 17-70 kDa (12) (13) (14) (15) (16) . CGRP activation results in increased levels of intracellular cAMP in endothelial cells and aorta (17, 18 ). An increase in cAMP can be monitored in oocytes by using the cystic fibrosis transmembrane conductance regulator (CFTR) as a reporter (19) . We have discovered a protein from the guinea pig organ of Corti that confers CGRP responsiveness to oocytes by using a
The publication costs of this article were defrayed in part by page (19, 23) . In other experiments, injected oocytes were separated into pools, and all oocytes of each pool were subjected to the same concentration of CGRP (10-10 M through 10-5 M). Antisense Injections. An antisense oligonucleotide containing a thiol-substituted backbone was synthesized to the 3' untranslated region of the CGRP-RCP cDNA (Fig. 4A, 6 (single species), a PCR product generated by using primer pairs 1 and 4 (Fig. 4a) Fig. 2b . A representative set of current traces from a single oocyte is shown in Fig. 3a (Fig. 4a) . The ORF is preceded by a 48-bp 5' untranslated region containing no upstream ATG codons and is followed by a 1232-bp 3' untranslated region containing stop codons distributed between all three reading frames. This cochlear cDNA was confirmed by direct sequencing of a reverse transcription-coupled PCR product amplified from cerebellar mRNA; cerebellum has been widely used as a source for CGRP binding studies (14) (15) (16) 34) . The two oligonucleotide primers used for PCR (labeled 1 and 2) are underlined in Fig. 4a . Two hundred nanograms of cerebellar poly(A)+ RNA was used as template for reverse transcription with the downstream oligonucleotide primer, and the resulting first-strand cDNA was used as template for PCR (24) . DNA sequence analysis detected no differences between the cochlear cDNA and the cerebellar reverse transcription-coupled PCR product.
Thus, the identical CGRP-RCP is present both in cerebellum and cochlea.
The 146-amino acid protein encoded by the ORF (Fig. 4a ) is largely hydrophilic (Fig. 4b) and has no homology to any reported receptor when searched against the GenBank database with BLAST software (35) . However, the BLAST search did identify an unpublished partial cDNA from a chicken lens cDNA library (expressed sequence tag, GenBank accession no. D26313). The protein predicted by this chicken cDNA has 70.5% amino acid identity with the guinea pig cochlear CGRP-RCP protein, using MEGALIGN (DNASTAR, Madison, WI) software.
Northern blot analysis from the guinea pig cerebellum revealed the size of the CGRP-RCP mRNA to be -1800 bp (Fig. 5) , similar in size to the cochlear CGRP-RCP cDNA, indicating that the cDNA contains most of the 5' untranslated sequence.
The size of the CGRP-RCP protein, as predicted by the nucleotide sequence, is consistent with data obtained by in vitro translation. In these experiments, a 20-kDa protein was detected after in vitro transcription of the cochlear CGRP-RCP cDNA, and subsequent in vitro translation and SDS/ PAGE, as shown in Fig. 6 . The addition of microsomal membranes did not alter the mobility of the translation product on SDS/PAGE, making post-translational modifications such Note the absence of currents from oocytes coinjected with the antisense CGRP-RCP oligonucleotide. Data are the mean ± SEM (n = 4). as glycosylation unlikely. An in vitro translation product of identical size to the cochlear receptor was detected when the cerebellar reverse transcription-coupled PCR product described above was used as a template for in vitro transcription (data not shown). PCR was carried out as described, except a T7 promoter sequence was incorporated into the 5' end of the upstream primer (Fig. 4a, primer 1 ) to enable subsequent in vitro transcription.
To confirm the identity of the cochlear CGRP-RCP, an antisense oligonucleotide was synthesized based on the sequence of the CGRP-RCP cDNA (Fig. 4a, primer 3 , doubleunderlined sequence). The antisense oligonucleotide to the cochlear CGRP-RCP eliminated receptor activity from both the cochlear receptor cRNA and cerebellar mRNA in the oocyte-CFTR assay, indicating that the cerebellum contains a CGRP-RCP homologous to that of the cochlear form (Fig. 7 ).
This conclusion agrees with the identical nucleotide sequence obtained from the cochlear cDNA and the cerebellar PCR product. (Fig. 8A) . In situ hybridization with the CGRP-RCP antisense RNA probe showed that the mRNA for the CGRP-RCP is also only present in outer hair cells of the basal two turns of the guinea pig cochlea (Fig. 8B ). This is in agreement with previous studies of CGRP's effect on high frequency regions (basal turns) of the guinea pig and rat cochleas (4, 8) . (14) . Because the cochlear CGRP-RCP protein is short and not obviously hydrophobic, it does not belong to the class of G-protein-coupled receptors that contain seven membranespanning helices. Two models could reconcile the primary structure of the CGRP-RCP with reports that CGRP binding is coupled to G-protein activation: (i) The CGRP-RCP could represent the complete CGRP receptor, which would contain an atypical membrane-spanning domain, in which case it might resemble the mannose-6-phosphate receptor, which couples to G proteins despite lacking the prototypical seven membranespanning helices (38) . (ii) The CGRP-RCP could be part of a complex of proteins that constitute the CGRP receptor. Such a complex has recently been described for the receptors for ciliary neurotrophic factor, interleukine 6, and type I interferon (39) (40) (41) . For the ciliary neurotrophic factor and interleukin 6 receptors, a small extracellular membrane-associated protein binds the ligand and interacts with a membranespanning protein for signal transduction, conferring specificity to a more generic signaling pathway. The CGRP-RCP may be contributing specificity in a similar manner. In this scenario, binding of CGRP to its receptor may activate the CFTR in the oocyte assay via a membrane-associated kinase, either in conjunction with, or separately from, the adenylate cyclase pathway depicted in Fig 1. Alternatively, the CGRP-RCP may couple the ligand-binding complex to the cellular signal transduction machinery. If the latter case, the CGRP-RCP is specific for bnly CGRP, as no other tested ligand could activate the oocyte-CFTR assay when tested with the CGRP-RCP. Whether the newly identified CGRP-RCP functions independently or in a complex of proteins remains to be determined.
